13F Filings History of Telemetry Investments, L.L.C.

Latest 13F report
Q4 2022 - 14 Feb 2023
Value $
$42,783,000
Signature - Title
Andrew Schorr - CEO
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Telemetry Investments, L.L.C.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Telemetry Investments, L.L.C. reported 140 stock holdings with total value $42,783,000 as of Q4 2022. Top holdings included SPKB, ATVI, ATYR, TCOA, and SHUAU.

Notify me when Telemetry Investments, L.L.C. files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2022 140 $42,783,000 +$12,746,731 -$29,944,929 -$17,198,198 SPKB, ATVI, ATYR, TCOA, SHUAU 13F-HR 14 Feb 2023, 09:14
Q3 2022 173 $61,037,000 +$20,168,684 -$24,093,254 -$3,924,570 SPKB, SHLX, ATVI, ATYR, CTXS 13F-HR 17 Nov 2022, 10:37
Q2 2022 176 $65,524,000 +$21,283,510 -$10,711,251 +$10,572,259 SPKB, ATVI, POND, XLE, EIGR 13F-HR 15 Aug 2022, 10:44
Q1 2022 164 $62,455,000 +$25,943,847 -$36,686,682 -$10,742,835 SPKB, XLE, POND, ATVI, EIGR 13F-HR 16 May 2022, 08:50
Q4 2021 175 $76,356,000 +$34,813,887 -$28,932,316 +$5,881,571 IWM, POND, SPKB, XLNX, QQQ 13F-HR 14 Feb 2022, 08:38
Q3 2021 158 $71,552,000 +$33,592,850 -$30,108,366 +$3,484,484 POND, SPKB, HWELU, APACU, XLNX 13F-HR 15 Nov 2021, 10:30
Q2 2021 138 $71,794,000 +$33,218,480 -$51,422,446 -$18,203,966 PONDU, SPKB, ALXN, WORK, XLNX 13F-HR 16 Aug 2021, 10:32
Q1 2021 126 $88,452,000 +$45,535,232 -$16,533,403 +$29,001,829 SPKBU, WTW, RSP, IPHI, WORK 13F-HR 17 May 2021, 10:05
Q4 2020 83 $54,429,000 +$21,183,758 -$16,523,393 +$4,660,365 VAR, WTW, IPHI, XLNX, EIGR 13F-HR 16 Feb 2021, 11:05
Q3 2020 67 $42,477,000 +$14,385,724 -$5,158,751 +$9,226,973 WTW, ETFC, VAR, KDMN, HGEN 13F-HR 16 Nov 2020, 09:21
Q2 2020 59 $33,130,000 +$18,206,624 -$14,009,091 +$4,197,533 KDMN, ETFC, BLPH, REGN, EIGR 13F-HR 14 Aug 2020, 12:10
Q1 2020 48 $25,429,000 +$12,070,031 -$10,212,042 +$1,857,989 AGN, KDMN, ZSAN, LOGM, EIGR 13F-HR 15 May 2020, 08:46
Q4 2019 40 $28,634,000 +$8,111,207 -$15,840,010 -$7,728,803 WCG, AGN, KDMN, DERM, EIGR 13F-HR 14 Feb 2020, 10:25
Q3 2019 51 $32,189,000 +$7,563,117 -$22,896,888 -$15,333,771 CELG, KDMN, EIGR, XTNT, WCG 13F-HR 14 Nov 2019, 11:50
Q2 2019 67 $50,048,000 +$26,583,191 -$23,069,554 +$3,513,637 KDMN, EIGR, XTNT, RHT, WCG 13F-HR 14 Aug 2019, 10:49
Q1 2019 79 $49,884,000 +$17,411,933 -$47,254,775 -$29,842,842 KDMN, DERMIRA INC, IDTI, XTNT, EIGR 13F-HR 15 May 2019, 10:16
Q4 2018 99 $74,739,000 +$44,046,980 -$25,108,728 +$18,938,252 KDMN, XLF, EEM, NOVAVAX INC, RHT 13F-HR 14 Feb 2019, 11:18
Q3 2018 85 $67,007,000 +$25,668,368 -$41,909,371 -$16,241,003 KDMN, PERNIX THERAPEUTICS HLDGS IN, NOVAVAX INC, ACORDA THERAPEUTICS INC, AET 13F-HR 14 Nov 2018, 11:47
Q2 2018 103 $83,429,000 +$35,017,391 -$44,659,664 -$9,642,273 KDMN, SPY, PERNIX THERAPEUTICS HLDGS IN, AET, DERMIRA INC 13F-HR 14 Aug 2018, 13:42
Q1 2018 107 $91,637,000 +$43,647,043 -$33,565,562 +$10,081,481 KDMN, AMAG PHARMACEUTICALS INC, PERNIX THERAPEUTICS HLDGS IN, AET, TWX 13F-HR 15 May 2018, 10:59
Q4 2017 82 $78,890,000 +$26,092,141 -$42,967,337 -$16,875,196 KDMN, AMAG PHARMACEUTICALS INC, TWX, PERNIX THERAPEUTICS HLDGS IN, ACORDA THERAPEUTICS INC 13F-HR 14 Feb 2018, 10:53
Q3 2017 103 $97,325,000 +$42,727,219 -$35,276,141 +$7,451,078 AMAG PHARMACEUTICALS INC, KDMN, PERNIX THERAPEUTICS HLDGS IN, PTC THERAPEUTICS INC, ACORDA THERAPEUTICS INC 13F-HR 14 Nov 2017, 12:35
Q2 2017 83 $89,134,000 +$45,011,274 -$49,914,724 -$4,903,450 AMAG PHARMACEUTICALS INC, KDMN, DEPOMED INC, OREXIGEN THERAPEUTICS INC, ACORDA THERAPEUTICS INC 13F-HR 14 Aug 2017, 12:07
Q1 2017 87 $89,524,000 +$46,778,925 -$31,581,649 +$15,197,276 ACORDA THERAPEUTICS INC, SUCAMPO PHARMACEUTICALS INC, OREXIGEN THERAPEUTICS INC, KDMN, PDL BIOPHARMA INC 13F-HR 15 May 2017, 11:27
Q4 2016 85 $74,724,000 +$29,454,188 -$43,992,474 -$14,538,286 ACORDA THERAPEUTICS INC, MON, AEGERION PHARMACEUTICALS INC, HUM, PTC THERAPEUTICS INC 13F-HR 14 Feb 2017, 12:04
Q3 2016 96 $87,308,000 +$38,111,366 -$46,451,491 -$8,340,125 LNKD, HUM, AEGERION PHARMACEUTICALS INC, ACORDA THERAPEUTICS INC, PTC THERAPEUTICS INC 13F-HR 14 Nov 2016, 11:30
Q2 2016 102 $92,468,000 +$32,783,015 -$50,173,675 -$17,390,660 HUM, SEQUENOM INC, AEGERION PHARMACEUTICALS INC, IOC, SPECTRANETICS CORP 13F-HR 15 Aug 2016, 13:56
Q1 2016 92 $111,605,000 +$41,294,726 -$77,393,645 -$36,098,919 HUM, AGN, TWC, SEQUENOM INC, CLOVIS ONCOLOGY INC 13F-HR 16 May 2016, 12:50
Q4 2015 114 $157,375,000 +$62,484,558 -$83,189,400 -$20,704,842 AEGERION PHARMACEUTICALS INC, CLOVIS ONCOLOGY INC, PCP, COBALT INTL ENERGY INC, SEQUENOM INC 13F-HR 16 Feb 2016, 10:19
Q3 2015 108 $180,422,000 +$103,433,495 -$67,733,660 +$35,699,835 EEM, OREXIGEN THERAPEUTICS INC, COBALT INTL ENERGY INC, FEZ, EXELIXIS INC 13F-HR 16 Nov 2015, 11:35
Q2 2015 157 $157,749,000 +$87,568,595 -$62,872,685 +$24,695,910 COBALT INTL ENERGY INC, OREXIGEN THERAPEUTICS INC, EXELIXIS INC, FDO, IOC 13F-HR 14 Aug 2015, 09:56
Q1 2015 180 $133,567,000 +$76,040,212 -$84,942,706 -$8,902,494 EXELIXIS INC, IOC, COBALT INTL ENERGY INC, ACORDA THERAPEUTICS INC, SLXP 13F-HR 15 May 2015, 14:22
Q4 2014 156 $138,168,000 $0 $0 $0 FEZ, COBALT INTL ENERGY INC, F113PS, EXELIXIS INC, IOC 13F-HR 22 Apr 2015, 15:27